Introduction
HIV and hepatitis B virus (HBV) co-infection is common in subSaharan Africa with HBV infection in HIV co-infection ranging from 5-17% in South Africa [1, 2] . HIV/HBV co-infection is associated with increased incidence of liver disease and, mortality [3, 4] , when compared to HBV monoinfection. Clinical treatment characteristics, which include HBeAg, HBV DNA, ALT, and baseline liver fibrosis, are important predictors of HBV disease progression and are also criteria for HBV treatment initiation. However, these laboratory indicators and how they may vary within populations and are not well characterised in HIV/HBV co-infection in African populations. Neither hepatitis B prevalence nor the distribution of its important clinical characteristics (HBeAg, HBV DNA, or liver fibrosis) may be uniform in subSaharan Africa, making application of guidelines that require these measurements a challenge in resource limited settings in Africa. Although HBV is considered endemic (.8%) in this region [5] , data in HBV mono-infection demonstrate wide variability's in HBV disease prevalence and its predictors of disease progression in Africa [6] .
The markers of particular clinical importance are HBeAg, HBV DNA, ALT, and baseline liver fibrosis. HBeAg is a marker for active HBV replication and elevated HBV DNA levels are associated with cirrhosis and hepatocellular carcinoma [7, 8] . Baseline liver fibrosis is indicative of disease progression. The FIB-4 score, a non-invasive marker for liver fibrosis has shown good sensitivity and specificity [9] for predicting mild and severe liver disease.
As HBV treatment paradigms in HIV co-infection evolve in resource limited settings, it will be important to identify baseline treatment characteristics, including the degree of liver disease, and whether there are regional differences that may influence the timing and initiation of ART in certain populations.
This study sought to identify baseline characteristics and their regional variation, including those characteristics indicative of disease progression and for the initiation of HBV therapy: HBeAg status, HBV viremia, ALT, and liver fibrosis in HIV/HBV coinfected patients initiating HIV therapy. We also sought to compare baseline characteristics in those with and without HBV co-infection. We analysed data from 812 participants from the CIPRA-SA 'Safeguard the household' study, a randomised controlled trial of ART monitoring strategies in a resource limited setting, whose primary objective was to evaluate HIV outcomes as a function of HIV care provided by nurses compared to doctors [10] .
Methods

Ethics Statement
The parent study was approved at the institutional review boards of the University of Witwatersrand and the University of Cape Town. Written informed consent was obtained from all participants before the initiation of study procedures in the parent study [10] . This current post-hoc analysis was performed on stored specimens and this stored specimen and database analysis was approved by the institutional review boards at the University of California, Los Angeles (UCLA) and the ethics committee at the University of the Witwatersrand, South Africa.
Study population and testing
This prospective study enrolled 812 participants over a two year period starting in February 2005 who were randomised to the nurse or doctor group. Participants were enrolled at two primary health-care sites. The Soweto Township is a more urbanised community with population estimates of 1.3 million. Masiphumelele in Cape Town is a peri-urban township established in 1992, currently home to 17,000 people. Participants were $18 years of age, had a CD4+ T-cell count ,350 cells/mm 3 or a previous AIDS defining illness, had no active opportunistic infections at the time of enrolment and were ART naive (excluding previous single dose NVP exposure and/or ,28 days of AZT exposure).
On enrolment CD4 count, HIV RNA, biochemistry (including AST, ALT) and haematology studies were performed. In addition, all participants were tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (Anti-HBs), hepatitis B e antigen (HBeAg), hepatitis B core antibody (Anti-HBc) with the Abbott AxSYM Micro-particle Enzyme Immunoassay (MEIA) (Wiesbaden, Germany) platform for Anti-HBs, Anti-HBc, Anti-HBe, HBeAg, HBsAg and HBV DNA, where sample was available. The FIB-4 score was used to assess liver fibrosis. A score of ,1.45 has a 90% predictive value of excluding advanced fibrosis [9] .
HBV DNA was tested using the Abbott RealTime HBV assay (Abbott Park, IL) a polymerase chain reaction (PCR) assay. Results were reported in IU/ml and the lower limit of detection of this assay was 10 IU/ml. Samples with viral loads .60 IU/ml had the pol region sequenced. HBV drug resistance testing was performed using a laboratory developed sequencing assay. This assay amplified and sequenced the polymerase gene of HBV [11] . The sequences were analysed using Sequencher version 4.8 and HBV drug resistance and genotype determined using the HBVseq tool on the Stanford HIV drug resistance database (http://hivdb. stanford.edu/HBV/HBVseq/development /HBVseq.html). To verify the genotypes obtained with the HBVseq tool, sequences were further aligned with reference sequences of HBV genotype A-G (GenBank reference sequences; Figure 1 ), using the Clustal W alignment option within MEGA version 5.10 [12] . On completion of alignment, neighbour-joining phylogenetic tree analysis was performed in MEGA version 5.10 [12] , using the p-distance bootstrap model. The stability of the nodes was assessed by bootstrap analysis (100 replicates), and bootstrap values greater than 70% were considered confident [13] .
Definitions: The term HBV infection is defined as a positive HBsAg test. The term occult HBV infection is defined as a negative HBsAg test but presence of HBV DNA [14, 15] . These two groups (HBV infection and occult HBV infection) were analyzed separately as those with occult HBV infection may have different clinical outcomes, when compared to HBV infection (defined as a positive HBsAg test).
Statistical Analysis
We compared continuous variables using T-tests or the Wilcoxon Rank Sum Test and discrete variables using chi-square tests and log-binomial regression [16] . For continuous variables we assessed normality using the Normal Probability Plot and the Shapiro-Wilk test. We used the T-test for normally distributed variables and the Wilcoxon Rank Sum Test for non-normally distributed variables. All analysis was performed using SAS version 9.1.3 Service Pack 4 (SAS Institute Inc., Cary, NC, USA).
Results
The study enrolled 812 HIV infected participants, 449 (55.3%) from the Soweto site in Johannesburg and 363 (44.7%) from the Masiphumelele site in Cape Town. 804 (99.0%) of the study participants were black African and 573 (70.0%) were women. The median age in of the overall HIV-infected cohort was 32.0 years and the median CD4 count was 165.0 cells per mL (IQR 110.5 to 229.0 cells per mL) at enrolment. Of the 812 HIV-infected participants, 48 (5.9%) were HBsAg positive. Occult HBV infection (HBsAg negative but detectable HBV DNA) was observed in 12 participants (1.5%).
Baseline Demographic and Serologic Characteristics in those with HBV Infection (HBsAg positive)
The median age of those with HBV infection was 29.5 years. Forty-four percent (21/48) were male. Excluding occult HBV infection, 51.9% of the cohort demonstrated exposure to HBV with at least one or more present of Anti-HBc, Anti-HBs, HBsAg, or HBV DNA. Only 2.7% of the cohort had serology consistent with vaccination (anti-HBs alone). Of the 48 HBsAg positive individuals, 28/48 (58.3%) were HBeAg positive. There were no differences in age or gender distribution in those with and without HBeAg ( Table 1) Median ALT, AST, and FIB-4 scores were also higher in those with HBeAg positive disease ( Table 1 ). Figure 1 . Phylogenetic Analysis of the 37 study entry samples (six digit number, two letters) with HBV pol sequence results and Genbank reference sequences (accession number genotype) at baseline. From this tree 32 sequences cluster with the reference genotype A sequences, four cluster with the genotype D reference sequences and one with the genotype E reference sequences. Bootstrap values on the tree referred to how rooted the phylogenetic tree is at the branch i.e. level of confidence. Note that samples identified as occult HBV infection are excluded from this analysis. 37 isolates were sequenced at baseline, one isolate was sequenced after baseline and was thus not included in the tree. 
Regional Differences
There were substantial differences in HBV infection: the prevalence in north-central South Africa in Soweto was 3.8% compared to south western South Africa, Masiphumelele, where the prevalence was 8.5% (relative risk 2.3; 95% CI: 1.3-4.0). Despite a higher prevalence of HBV infection, more participants in Masiphumelele had HBeAg-negative chronic HBV (58% vs. 12%; p = 0.002), a type associated with less severe disease. Differences in HBeAg status were also reflected in HBV DNA levels; the median HBV DNA in HBeAg+ and HBeAg (2) HBV was 2.9610 8 and 3.5610 2 IU/ml, respectively (p,.0001) and median HBV DNA levels between sites was 2.7610 8 and 5.8610
5 IU/ml in Soweto and Masiphumelele, respectively. Twenty nine and eight tenths percent (29.8%) of all HIV/HBV co-infected participants had HBV DNA levels #2000 IU/ml and 33% of participants had HBV DNA levels #20,000 IU/ml. However, more HIV/HBV co-infected participants in Masiphumelele had HBV DNA levels #2000 IU/ml (43% vs. 6%; p,0.007) and more participants in Soweto had both an elevated ALT and HBV DNA$2000 IU/ML (35% vs. 24%), but this did not reach statistical significance. There was no difference, however, in median FIB-4 scores between HIV/HBV co-infected participants between treatment sites ( Table 2) . 
Molecular Characteristics
Of the 48 participants that were HBsAg positive, 38 were successfully sequenced during the study, genotype A was the predominant genotype and occurred in 87% (33/38) of cases, followed by genotype D at 10% (4/38), genotype E was observed in one subject. In Soweto all the genotypes identified were genotype A apart from a single case of genotype E. In Masiphumelele the participants were both genotype A and D. There was no HBV drug resistance, as measured by consensus sequencing, at baseline. Figure 1 depicts the phylogenetic relatedness of the HBV isolates. 
Comparison between HBV genotypes and baseline characteristics
Occult HBV infection
In this cohort, 12 individuals with occult HBV infection were identified; these individuals had HBV DNA in the absence of any serologic marker for HBV. The median CD4 was 112.5. Median HBV viral load was 2.5610 2 IU/ml and median FIB-4 score was 1.0.
Discussion
In a South African HIV-1 treatment-naïve cohort, HIV/HBV co-infected participants had low levels of liver disease, as measured by FIB-4 scores. Additionally, despite low CD4 counts (CD4,350), only 30% of individuals had both an HBV DNA.2000 IU/ml and elevated ALT which meet the treatment criteria as proposed by Soriano [17] . There were also substantial regional differences in HBV/HIV co-infection and its baseline treatment characteristics in Southern Africa. These factors may impact clinical decision making in HIV/HBV co-infection individuals in sub-Saharan Africa, especially in those populations where assessment of liver disease and HBV viral loads are important to clinical decision-making. Our study shows differences in baseline predictors of liver disease when compared to Asian, European, or US cohorts, where HBeAg prevalence and HBV DNA levels are higher in HIV/HBV coinfected individuals [18] [19] . Other cohorts with higher enrolment from African sites, however, have shown similar lower prevalences of HBeAg-positive disease and low HBV DNA levels [20] [21] [22] . Thio and colleagues demonstrated that 66% of patients had HBV DNA,2000 IU/ml [20] and a Nigerian study demonstrated lower HBV DNA levels than US and European cohorts [22] . One explanation may be a difference in HBV genotypes; in one study HBV genotypes D,E, and F were associated with HBeAg-positive disease [20] . Another reason may be the timing of acquisition of infection; in African sites, most infections are thought to arise from horizontal transmission and these infections may be associated with a higher degree of HBeAg clearance, and subsequently, lower HBV viral loads.
The finding of regional differences in sub-Saharan Africa has also been noted in HBV monoinfection and HIV/HBV coinfection but this is the first large study to demonstrate such differences in HIV/HBV co-infection within one country, where HBV treatment guidelines are likely to be standardized. In South Africa, regional differences in have been reported in HBV monoinfected and HIV/HBV co-infected cohorts; low prevalences of HBV infection have been reported in Johannesburg in HIV/ HBV co-infection [23] while HBV infection prevalence in an HIV uninfected population in the Eastern Cape, in both urban and rural areas, was 10.4% [24] . Others have found that HBsAg prevalence is higher in rural areas [25, 26] . Such regional variations may be attributable to both age at acquisition and difference in HBV genotypes. Alternatively, practices associated with HBV transmission, such as scarification, may be more common in rural areas.
Current WHO recommendations for the treatment of HIV/ HBV co-infection are for initiation of antiretroviral therapy for those with chronic active HBV infection [27] . This definition is evolving but one guideline recommends its definition as an HBV DNA level $2000 IU/ml and an elevated ALT [17] . Our data demonstrate that up to 30% of HIV/HBV co-infected individuals in a South African clinical trial have low HBV DNA levels, 88% have low levels of fibrosis, and that there is regional variation in HBV disease. These findings will impact populations where regional variations exist and WHO recommendations for the treatment of chronic active hepatitis are followed, which may require testing for HBeAg and HBV DNA. These findings will also impact cohorts where low HBV viral loads and presence/absence of significant liver disease may change treatment decisions. Such populations include pregnant women, where HBV viral loads are predictors of perinatal HBV transmission and the long term data on the safety of in utero exposure to TDF are still being studied, and HIV/HBV coinfected individuals with preexisting or emerging renal disease who may not have access to other HBV therapies such as entecavir or pegylated interferon. Future questions include the optimal timing of initiation in HIV/HBV co-infected individuals and a longitudinal examination of populations with low fibrosis scores and low HBV DNA levels in African HIV/ HBV co-infected populations.
